aaa

No. 36x, ?? 2000

2000 Archive Index aaaa Search aaaa Subscriber Area aaaa Home
Next Issueaaaa Previous Issue


Japanese Companies in the United States


American Companies In Japan

2000 Archive Index aaaa Search aaaa Subscriber Area aaaa Home
Next Issueaaaa Previous Issue


Japanese Companies in the U.S.


CHEMICALS

Additional supplies of liquid polyimide materials for semiconductor applications are coming on the market with the start-up of a second HD MICROSYSTEMS L.L.C. plant in Parlin, New Jersey. The new facility turns out high-molecular-weight polyimide coatings and photodefinable polyimides -- materials that are used for stress buffer and wafer overcoat as well as for dielectric and passivation layers in chips and thin-film packages. Year-old- plus HD MicroSystems, equally owned by HITACHI CHEMICAL CO., LTD. and E.I. DUPONT DE NEMOURS & CO., INC., spent approximately $12 million to build a facility with a Class 10,000 cleanroom manufacturing area, a Class 100 cleanroom for filtration and bottling and a Class 10 cleanroom for quality control and functional testing. The new plant in Parlin, which roughly doubles capacity at that location, manufactures the same products as the joint venture's Yamazaki Works in Hitachi City, Ibaraki prefecture.

An exchange rate of ¥1??=$1.00 was used in this report.

Top aaaaa Subscriber Area aaaa Home


American Companies in Japan


CHEMICALS

By 2005, DOW CHEMICAL CO. hopes to supply between 8 percent and 10 percent of Japan's low-density polyethylene market, which is projected to be 2.2 million-plus tons that year. To reach this goal, the company plans to quadruple sales of high-performance linear LDPE, which provides superior durability among other desirable characteristics. Dow also will use its new Polyolefin Technical Center in Singapore and a similar facility in Japan to develop value-added polyethylene products for the Japanese market. Palo Alto, California's GENEASIA, INC. and Tokyo-based CMIC CO., LTD., Japan's largest provider of contract research organization services to the pharmaceutical industry, have set out to pioneer a new type of CRO business. In addition to traditional clinical testing services, it will provide contract research based on pharmacogenomics, GeneAsia's specialty. Pharmacogenomics uses genetics to better understand drug pharmacology. It is said to enhance the clinical assessment of drug profiles and also to ensure that new drug compounds have greater efficacy and lower toxicity. Diabetes, hypertension, arteriosclerosis and obesity are the initial disease targets of the pharmacogenomics studies offered by GeneAsia and CMIC.

An exchange rate of ¥1??=$1.00 was used in this report.

Top aaaaa Subscriber Area aaaa Home